SLN Insider Griffiths Buys 62,457 ADS at $5.65-$6.00 鈥� Form 4

Q: How many Silence Therapeutics (SLN) ADS did Richard Ian Griffiths purchase?

He bought 62,457 ADS over three consecutive trading days.

Q: What prices were paid for the SLN ADS?

Prices ranged from $5.65 to $6.00 per ADS.

Q: What is the insider's total beneficial ownership after the trades?

Griffiths now directly owns 11,687,365 ADS.

Q: Do the transactions involve a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the purchases were made under a Rule 10b5-1 plan.

[8-K] Omega Healthcare Investors Inc. Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) 鈥� Form 4 insider activity

Director and more-than-10% shareholder Richard Ian Griffiths reported a series of open-market purchases of the company鈥檚 American Depositary Shares (ADS) between 7 and 9 July 2025.

07 Jul 2025: 7,937 ADS at $5.65
08 Jul 2025: 24,387 ADS at $5.94
09 Jul 2025: 30,133 ADS at $6.00

The three trades total 62,457 ADS. Each ADS is convertible into three ordinary shares, equating to 187,371 ordinary shares added to his stake.

Following the last transaction, Griffiths鈥� direct beneficial ownership stands at 11,687,365 ADS. All transactions were coded 鈥淧鈥� (purchase) and no dispositions or derivative exercises were reported. No Rule 10b5-1 trading plan was indicated.

The filing signals continued accumulation by a key insider but contains no additional financial or operational disclosures.

Positive

Insider confidence: A director and >10% shareholder increased his stake by 62,457 ADS, signalling continued confidence.
No dispositions: Only purchases were reported; no sales or option exercises that might offset the positive signal.

Negative

None.

Insights

TL;DR: 10% holder buys 62k SLN ADS at market prices; a modestly positive but not material signal.

Griffiths鈥� purchases add roughly 0.5% to his already large position, taking him to 11.7 million ADS. The transactions were small relative to average daily volume and do not meaningfully alter the ownership structure, yet insider buying鈥攅specially from a long-term, high-percentage holder鈥攖ends to be interpreted as confidence in future prospects. No sales, option exercises, or 10b5-1 plan disclosures were noted, reinforcing the voluntary nature of the buys. From a valuation perspective the dollar outlay (鈮� $370 k) is immaterial to corporate finances and therefore market impact is likely limited.

07/10/2025 - 08:36 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2025

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

Maryland

1-11316

38-3041398

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

303 International Circle

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

(410) 427-1700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.10 par value	OHI	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On July 10, 2025, Omega Healthcare Investors, Inc. (“Omega” or the “Company”) issued a press release announcing that it had posted to its website, www.omegehealthcare.com, under the Investor Relations section and under the News & Events section, an updated investor presentation which includes a revised Operator Updates slide on page 9 of the presentation. The updated investor presentation is titled “July 2025 Investor Presentation.” The presentation will remain on the Company’s website for a period of at least thirty days. Omega’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth herein and in Exhibit 99.1 is furnished pursuant to Item 7.01–Regulation FD Disclosure and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section nor shall the information be deemed incorporated by reference in any filing of the Company.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.	Description of Exhibit

99.1	Press release issued by the Company dated July 10, 2025.

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

[The balance of this page is intentionally left blank.]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OMEGA HEALTHCARE INVESTORS, INC.

Dated: July 10, 2025	By:	/s/ Gail D. Makode
		Gail D. Makode
		Chief Legal Officer, General Counsel

Source:

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Ian Griffiths purchase?

He bought 62,457 ADS over three consecutive trading days.

What prices were paid for the SLN ADS?

Prices ranged from $5.65 to $6.00 per ADS.

What is the insider's total beneficial ownership after the trades?

Griffiths now directly owns 11,687,365 ADS.

Do the transactions involve a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the purchases were made under a Rule 10b5-1 plan.

How many ordinary shares do the purchased ADS represent?

Because each ADS equals three ordinary shares, the purchases correspond to 187,371 ordinary shares.

Were any securities sold in these Form 4 transactions?

No. All reported transactions were coded "P" (purchase); no dispositions were reported.

AG真人官方

[8-K] Omega Healthcare Investors Inc. Reports Material Event

Insights

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Ian Griffiths purchase?

What prices were paid for the SLN ADS?

What is the insider's total beneficial ownership after the trades?

Do the transactions involve a Rule 10b5-1 trading plan?

How many ordinary shares do the purchased ADS represent?

Were any securities sold in these Form 4 transactions?

NYSE:OHI

OHI Rankings

OHI Latest News

OHI Latest SEC Filings

OHI Stock Data

AG真人官方

Trending News

[8-K] Omega Healthcare Investors Inc. Reports Material Event

Insights

Financial Analyst neutral

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Ian Griffiths purchase?

What prices were paid for the SLN ADS?

What is the insider's total beneficial ownership after the trades?

Do the transactions involve a Rule 10b5-1 trading plan?

How many ordinary shares do the purchased ADS represent?

Were any securities sold in these Form 4 transactions?

NYSE:OHI

OHI Rankings

OHI Latest News

OHI Latest SEC Filings

OHI Stock Data